Allergan cyclosporine ophthalmic
Executive Summary
FDA's Dermatologic & Ophthalmic Drugs Advisory Committee will meet July 21 to discuss Allergan's NDA for cyclosporine ophthalmic emulsion .05% for treatment of keratoconjunctivitis sicca. The meeting begins at 8:30 a.m. at the Hilton in Gaithersburg, Md